Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 61 - 70 of 229 items for :

Clear All
Milou Cecilia Madsen Department of Internal Medicine and Center of Expertise on Gender Dysphoria, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

Search for other papers by Milou Cecilia Madsen in
Google Scholar
PubMed Close
,
Martin den Heijer Department of Internal Medicine and Center of Expertise on Gender Dysphoria, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

Search for other papers by Martin den Heijer in
Google Scholar
PubMed Close
,
Claudia Pees Walaeus Library, Leiden University Medical Center, Leiden, the Netherlands

Search for other papers by Claudia Pees in
Google Scholar
PubMed Close
,
Nienke R Biermasz Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands

Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed Close
, and
Leontine E H Bakker Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands

Search for other papers by Leontine E H Bakker in
Google Scholar
PubMed Close

)  Chiang 2007 (42), Double-blind, randomized, placebo-controlled study Gel/placebo 40 men with hypogonadism 3 months Improvement of sexual function  Cunningham 2017 (26), Phase 3 open-label non-comparator study Gel/none 160 men with

Article Type:
Review Article
Collections:
Reproduction
DOI:
https://doi.org/10.1530/EC-22-0112
Volume/Issue:
Volume 11: Issue 8
Open access
Richard J Auchus Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA
Veterans Affairs Medical Center, Ann Arbor, Michigan, USA

Search for other papers by Richard J Auchus in
Google Scholar
PubMed Close

programs extract a substantial toll from these victims and the healthcare system over time. As the enhanced sense of well-being that largely derives from the placebo effect ( 9 ) rapidly wane, the usual response is dose escalation or adding yet another form

Article Type:
Article Commentary
DOI:
https://doi.org/10.1530/EC-21-0039
Volume/Issue:
Volume 10: Issue 9
Open access
M Ahmid Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

Search for other papers by M Ahmid in
Google Scholar
PubMed Close
,
C G Perry Department of Endocrinology, Queen Elizabeth University Hospitals, Glasgow, UK

Search for other papers by C G Perry in
Google Scholar
PubMed Close
,
S F Ahmed Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

Search for other papers by S F Ahmed in
Google Scholar
PubMed Close
, and
M G Shaikh Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

Search for other papers by M G Shaikh in
Google Scholar
PubMed Close

composition CVS risks Glucose metabolism QOL ( 39 ) ( 56 ) 18 15/3 20.2±1 2 years RCT n =9 on rhGH n =10 on placebo 3.6IU/day – – ↑ 6% in LM in rhGH ↓ 6% FM in rhGH ↔ ↓ IS in rhGH ↔ a ( 4 ) ( 40 ) 24 20/4 17

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-16-0024
Volume/Issue:
Volume 5: Issue 3
Open access
Espen Nordheim Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Faculty of Medicine, University of Oslo, Oslo, Norway

Search for other papers by Espen Nordheim in
Google Scholar
PubMed Close
and
Trond Geir Jenssen Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Faculty of Medicine, University of Oslo, Oslo, Norway
Metabolic and Renal Research Group, Faculty of Health Sciences, UiT- The Arctic University of Norway, Tromsø

Search for other papers by Trond Geir Jenssen in
Google Scholar
PubMed Close

patients with kidney disease ( 51 ). This was a randomized placebo-controlled trial of more than 4000 type 2 diabetes patients with estimated glomerular filtration rate (eGFR) between 30 and 90 mL/min/1.73 m 2 and UACR ranging 300–5000 mg/g. The pre

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-21-0097
Volume/Issue:
Volume 10: Issue 5
Open access
Jonathan Hazlehurst Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Search for other papers by Jonathan Hazlehurst in
Google Scholar
PubMed Close
,
Bernard Khoo Endocrinology, Division of Medicine, University College London, London, UK

Search for other papers by Bernard Khoo in
Google Scholar
PubMed Close
,
Carolina Brito Lobato Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Medicine, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark

Search for other papers by Carolina Brito Lobato in
Google Scholar
PubMed Close
,
Ibiyemi Ilesanmi Section of Endocrinology and Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK

Search for other papers by Ibiyemi Ilesanmi in
Google Scholar
PubMed Close
,
Sally Abbott Department of Dietetics, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK

Search for other papers by Sally Abbott in
Google Scholar
PubMed Close
,
Tin Chan Faculty of Medicine, Chinese University of Hong Kong, Hong Kong

Search for other papers by Tin Chan in
Google Scholar
PubMed Close
,
Sanesh Pillai Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK

Search for other papers by Sanesh Pillai in
Google Scholar
PubMed Close
,
Kate Maslin School of Nursing and Midwifery, University of Plymouth, Plymouth, UK

Search for other papers by Kate Maslin in
Google Scholar
PubMed Close
,
Sanjay Purkayastha Brunel University, London, UK
Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK

Search for other papers by Sanjay Purkayastha in
Google Scholar
PubMed Close
,
Barbara McGowan Endocrinology, Guys’ and St Thomas’s NHS Foundation Trust, London, UK

Search for other papers by Barbara McGowan in
Google Scholar
PubMed Close
,
Rob Andrews University of Exeter Medical School, Exeter, UK

Search for other papers by Rob Andrews in
Google Scholar
PubMed Close
,
Eveleigh Nicholson Portsmouth Hospitals University NHS Trust, Portsmouth, UK

Search for other papers by Eveleigh Nicholson in
Google Scholar
PubMed Close
,
Katherine McCullough Royal Surrey County Hospital, Guildford, UK

Search for other papers by Katherine McCullough in
Google Scholar
PubMed Close
,
Lorraine Albon University Hospitals Sussex NHS Foundation Trust, Worthing, UK

Search for other papers by Lorraine Albon in
Google Scholar
PubMed Close
,
Rachel Batterham Endocrinology, Division of Medicine, University College London, London, UK

Search for other papers by Rachel Batterham in
Google Scholar
PubMed Close
,
Georgios K Dimitriadis King's College Hospital NHS Foundation Trust, London, UK

Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed Close
,
Shareen Forbes BHF Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

Search for other papers by Shareen Forbes in
Google Scholar
PubMed Close
,
Gavin Bewick School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK

Search for other papers by Gavin Bewick in
Google Scholar
PubMed Close
, and
Tricia M-M Tan Section of Endocrinology and Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK

Search for other papers by Tricia M-M Tan in
Google Scholar
PubMed Close

recommended international non-proprietary name avexitide) leads to the correction of hypoglycaemia and reduced hyperinsulinaemia in response to an MMT or OGTT and reduced hypoglycaemic symptoms in people with PBH ( 10 , 107 , 108 , 109 ). A phase II placebo

Article Type:
Other
Collections:
Metabolic Syndrome and Diabetes
DOI:
https://doi.org/10.1530/EC-23-0285
Volume/Issue:
Volume 13: Issue 5
Open access
Elizabeth Micks Department of Obstetrics and Gynecology, Department of Research, University of Washington, Box 356460, 1959 NE Pacific Street, Seattle, Washington, USA

Search for other papers by Elizabeth Micks in
Google Scholar
PubMed Close
,
Greta B Raglan Department of Obstetrics and Gynecology, Department of Research, University of Washington, Box 356460, 1959 NE Pacific Street, Seattle, Washington, USA

Search for other papers by Greta B Raglan in
Google Scholar
PubMed Close
, and
Jay Schulkin Department of Obstetrics and Gynecology, Department of Research, University of Washington, Box 356460, 1959 NE Pacific Street, Seattle, Washington, USA
Department of Obstetrics and Gynecology, Department of Research, University of Washington, Box 356460, 1959 NE Pacific Street, Seattle, Washington, USA

Search for other papers by Jay Schulkin in
Google Scholar
PubMed Close

. In one study, 29/74 women in the oral progesterone group vs 44/79 women in the placebo group had a preterm delivery at <37 weeks ( P =0.002) (49) . Decreased risk of preterm delivery has been achieved with vaginal progesterone gel, though one study

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-15-0093
Volume/Issue:
Volume 4: Issue 4
Open access
Bernardo Maia Neuroendocrinology Research Center/Endocrinology Division – Medical School and Hospital Universitário Clementino Fraga Filho – Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Search for other papers by Bernardo Maia in
Google Scholar
PubMed Close
,
Leandro Kasuki Neuroendocrinology Research Center/Endocrinology Division – Medical School and Hospital Universitário Clementino Fraga Filho – Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Endocrinology Division – Hospital Federal de Bonsucesso, Rio de Janeiro Brazil

Search for other papers by Leandro Kasuki in
Google Scholar
PubMed Close
, and
Mônica R Gadelha Neuroendocrinology Research Center/Endocrinology Division – Medical School and Hospital Universitário Clementino Fraga Filho – Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Neuropatology and Molecular Genetics Laboratory – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil

Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed Close

and acromegaly disease burden, with no safety signal related to the novel formulation and route of administration ( 45 ). Oral octreotide was also evaluated in a 9-month phase 3 double-blind, randomized, placebo-controlled, multicenter study designed

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0433
Volume/Issue:
Volume 9: Issue 12
Open access
Herjan J T Coelingh Bennink Pantarhei Oncology, Zeist, The Netherlands

Search for other papers by Herjan J T Coelingh Bennink in
Google Scholar
PubMed Close
,
Jan Krijgh Pantarhei Oncology, Zeist, The Netherlands

Search for other papers by Jan Krijgh in
Google Scholar
PubMed Close
,
Jan F M Egberts Terminal 4 Communications, Hilversum, The Netherlands

Search for other papers by Jan F M Egberts in
Google Scholar
PubMed Close
,
Maria Slootweg Independent Consultant, Zeist, The Netherlands

Search for other papers by Maria Slootweg in
Google Scholar
PubMed Close
,
Harm H E van Melick Department of Urology, St. Antonius Hospital, Nieuwegein, The Netherlands

Search for other papers by Harm H E van Melick in
Google Scholar
PubMed Close
,
Erik P M Roos Department of Urology, Antonius Hospital, Sneek, The Netherlands

Search for other papers by Erik P M Roos in
Google Scholar
PubMed Close
,
Diederik M Somford Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

Search for other papers by Diederik M Somford in
Google Scholar
PubMed Close
,
Yvette Zimmerman Pantarhei Oncology, Zeist, The Netherlands

Search for other papers by Yvette Zimmerman in
Google Scholar
PubMed Close
,
Iman J Schultz Pantarhei Oncology, Zeist, The Netherlands

Search for other papers by Iman J Schultz in
Google Scholar
PubMed Close
,
Noel W Clarke The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK

Search for other papers by Noel W Clarke in
Google Scholar
PubMed Close
,
R Jeroen A van Moorselaar Department of Urology, Amsterdam UMC, VU University, Amsterdam, The Netherlands

Search for other papers by R Jeroen A van Moorselaar in
Google Scholar
PubMed Close
, and
Frans M J Debruyne Andros Clinics, Arnhem, The Netherlands

Search for other papers by Frans M J Debruyne in
Google Scholar
PubMed Close

.9 or 1.8 mg E2 gel per day or matching placebo ( 43 ). After 28 days, type 1 collagen C-telopeptide (CTX1) levels were significantly decreased in the combined tE2 groups compared to placebo ( P  < 0.001). In a nested BMD substudy of the tE2 PATCH

Article Type:
Review Article
Collections:
Bone and Mineral Metabolism
DOI:
https://doi.org/10.1530/EC-22-0182
Volume/Issue:
Volume 11: Issue 12
Open access
Angelica Lindén Hirschberg Division of Obstetrics and Gynaecology, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.

Search for other papers by Angelica Lindén Hirschberg in
Google Scholar
PubMed Close

). Recently in our double-blind, randomized, placebo-controlled study (RCT), 48 healthy, physically active women, 18–35 years of age, were allocated randomly to 10 weeks of daily treatment with 10 mg testosterone cream or placebo cream ( 55 ). In those

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-19-0537
Volume/Issue:
Volume 9: Issue 4
Open access
Jakub Supronik Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland

Search for other papers by Jakub Supronik in
Google Scholar
PubMed Close
,
Małgorzata Szelachowska Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland

Search for other papers by Małgorzata Szelachowska in
Google Scholar
PubMed Close
,
Adam Kretowski Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland

Search for other papers by Adam Kretowski in
Google Scholar
PubMed Close
, and
Katarzyna Siewko Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland

Search for other papers by Katarzyna Siewko in
Google Scholar
PubMed Close

Randomized, prospective, and double-blinded RTX 2 × 1000 mg 13 20 (9–60) 4.9 (1.0) 3.7 (1.9) 2 4/13 at week 24 No significant difference between groups in disease severity No data 5 moderate/severe Placebo n.a. 12 19.5 (2

Article Type:
Review Article
Collections:
Thyroid
DOI:
https://doi.org/10.1530/EC-22-0303
Volume/Issue:
Volume 11: Issue 12
Open access